Baron Bruce M, Cregge Robert J, Farr Robert A, Friedrich Dirk, Gross Raymond S, Harrison Boyd L, Janowick David A, Matthews Donald, McCloskey Timothy C, Meikrantz Scott, Nyce Philip L, Vaz Roy, Metz William A
Department of Medicinal Chemistry, Aventis Pharmaceuticals, Route 202-206, Bridgewater, New Jersey 08807-0800, USA.
J Med Chem. 2005 Feb 24;48(4):995-1018. doi: 10.1021/jm0491849.
(E)-3-(2-Carboxy-2-phenylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acid, 1, is a potent and selective antagonist of the glycine site of the N-methyl-d-aspartate (NMDA) receptor. Using 3D comparative molecular field analysis (CoMFA) to guide the synthetic effort, a series of aryl diacid analogues of 1 were synthesized to optimize in vivo potency, duration of action, and binding activity. It was found that the incorporation of a substituted aromatic with an electron withdrawing group or a heterocyclic group at the 2-position of the 3-propenyl moiety of 1 gave compounds with better affinity and potency in the murine stroke model. Ultimately this led to the discovery of 3-[2-(3-aminophenyl)-2-carboxyvinyl]-4,6-dichloro-1H-indole-2-carboxylic acid, 19, as a new potent selective glycine-site NMDA receptor antagonist.
(E)-3-(2-羧基-2-苯基乙烯基)-4,6-二氯-1H-吲哚-2-羧酸(1)是N-甲基-D-天冬氨酸(NMDA)受体甘氨酸位点的强效选择性拮抗剂。利用三维比较分子场分析(CoMFA)指导合成工作,合成了一系列1的芳基二酸类似物,以优化体内效力、作用持续时间和结合活性。发现在1的3-丙烯基部分的2-位引入带有吸电子基团的取代芳烃或杂环基团,可得到在小鼠中风模型中具有更好亲和力和效力的化合物。最终发现了3-[2-(3-氨基苯基)-2-羧基乙烯基]-4,6-二氯-1H-吲哚-2-羧酸(19),它是一种新型强效选择性甘氨酸位点NMDA受体拮抗剂。